News Breaks |
|
|
| December 11, 2012 |
| 18:16 EDT |  | THRX | Theravance initiates Phase 2b study with TD-4208
Theravance announced the initiation of a dose ranging Phase 2b study with TD-4208 as a nebulized aqueous solution in patients with moderate to severe COPD. TD-4208 is an investigational inhaled long-acting muscarinic antagonist, discovered using Theravance's multivalent approach to drug design. This compound is under development by Theravance for the treatment of chronic obstructive pulmonary disease, or COPD. |
|
|
News For THRX From The Last 14 Days Check below for free stories on THRX the last two weeks. |
|
|
| May 21, 2013 |
| 07:07 EDT |  | THRX | Theravance pullback on Elan bid a buying opportunity, says Piper Jaffray
 Subscribe for More Information |
|
| May 16, 2013 |
| 11:27 EDT |  | THRX | Options with decreasing implied volatility: LNCO MBI OPK THRX SGMO
Subscribe for More Information |
|
| May 15, 2013 |
| 11:13 EDT | | THRX | Options with decreasing implied volatility: MM GMCR GRPN THRX SGMO
Subscribe for More Information |
|
| May 14, 2013 |
| 12:16 EDT | | THRX | Options with decreasing implied volatility: MM PANL DGIT VCLK THRX
Subscribe for More Information |
|
| 08:16 EDT | | THRX | Theravance price target raised to $48 from $38 at RW Baird
Subscribe for More Information |
|
| 07:07 EDT | | THRX | Theravance price target raised to $54 from $44 at Stifel
Stifel thinks that Theravance's (THRX) royalty deal with Elan (ELN) demonstrates its ability to generate revenue that had not been reflected in its stock price. The firm expects Theravance to make similar deals in the future and it keeps a Buy rating on the stock. |
|
| May 13, 2013 |
| 16:25 EDT |  | THRX | On The Fly: Closing Wrap
Stocks on Wall Street were little changed from their opening levels as investors weighed the potential end of the Fed's quantitative easing program against a better than expected report on retail sales. The Wall Street Journal's Jon Hilsenrath suggested in a report over the weekend that the Federal Reserve has mapped a QE exit strategy. The report paired with the retail sales data left the market lacking conviction in either direction today, as the averages spent the majority of the session range-bound near the flatline. ECONOMIC EVENTS: In the U.S., retail sales rose 0.1% in April, which beat expectations for a 0.3% decline. Retail sales excluding autos, gas, and building materials rose 0.6%, which was also better than expected. Business inventories were flat in March, versus expectations for a 0.3% gain. In Asia, Chinese factory output grew 9.3% annually in April, which was up from 8.9% in March but still missed expectations for a 9.5% growth rate. COMPANY NEWS: The Supreme Court ruled unanimously that Monsanto's (MON) patented genetically altered soybeans are protected and that farmers cannot use them to create new seeds without paying the company... Dell's (DELL) special committee publicly asked for more information from Carl Icahn and Southeastern Asset Management about their proposed leveraged recapitalization. This request follows television interviews by Icahn last Friday in which he discussed his Dell proposal, as well as a weekend report in Barron's saying the Icahn and Southeastern plan could be a better deal for shareholders. MAJOR MOVERS: Among the notable gainers was Theravance (THRX), up $6.26, or 17.92%, to $41.20 after Elan Corporation (ELN) bought a stake in the potential future royalty payments from four respiratory programs partnered with GlaxoSmithKline (GSK) in exchange for $1B in cash. Also higher was Tesla (TSLA), which rose $11.04, or 14.38%, to $87.80 in its third straight double-digit percentage gain following a better-than-expected earnings report last week. Among the noteworthy losers was Barnes & Noble (BKS), down $2.21, or 9.48%, to $21.10 after the blog InsiderMonkey disputed a previous report about Microsoft's (MSFT) interest in the bookseller's NOOK assets. Also lower was JoS. A. Bank (JOSB), down $3.31, or 7.16%, to $42.90 after the company's first quarter earnings view came in below expectations. INDICES: The Dow was down 26.81, or 0.18%, to 15,091.68; the Nasdaq was up 2.21, or 0.06%, to 3,438.79; and the S&P 500 was nearly unchanged at 1,633.77. |
|
| 12:20 EDT | | THRX | On The Fly: Midday Wrap
Subscribe for More Information |
|
| 09:25 EDT | | THRX | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 05:44 EDT | | THRX | Elan provides additional information on Elan/Theravance agreement
Subscribe for More Information |
| |
| 05:35 EDT | | THRX | Theravance, Elan enter into $1B royalty participation agreement
Subscribe for More Information |
|
| 05:31 EDT | | THRX | Theravance, Elan enter into $1B royalty participation agreement
|
|
| 05:26 EDT |  | THRX | Theravance to host conference call
Subscribe for More Information |
|
| May 10, 2013 |
| 12:42 EDT | | THRX | GlaxoSmithKline, Theravance confirm FDA approval of Breo Ellipta
Subscribe for More Information |
|
| 11:17 EDT | | THRX | Theravance jumps 12% to $35.12 following FDA approval for COPD drug
Subscribe for More Information |
|
| 11:15 EDT | | THRX | FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease
Subscribe for More Information |
|
| May 9, 2013 |
| 06:12 EDT | | THRX | Theravance price target raised to $44 from $32 at Piper Jaffray
Subscribe for More Information |
|
|
|
|
|
